Genmab — Juli 2020
-
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Halozyme to $31 from $28 and keeps an Overweight rating on the shares after speaking with a key opinion leader from a large academic center to gauge where Darzalex Faspro was in the adoption cycle. Through an accelerated process due to COVID, Darzalex Faspro has been approved for usage in the outpatient setting at this center beginning next week, Catanzaro tells investors in a research note.
-
The analyst does not expect, consistent with Halozyme guidance, meaningful royalties in Q2. However, Catanzaro believes Q3 could see realization of IV to subQ conversion based on the KOL's feedback that the majority of patients could be easily converted.
-
I don't know Mcjean. But Q4ish certainly is what I was looking for, i think speedy approvals surprised most a bit, specially in europe. And in additioin, where Covid most likely will slow down most medicine launches, it actually appears to probably speed up the launch and implementation for SC
-
Det ser sådan ud lige nu.
-
Puha ja.
-
Næsten 60.000 stk igennem slutauktionen.
-
Hans analyse sige vel også, at ketchupeffekten for alvor sker i det niveau?
or make you loose your patience because you get high on Genmab and the news ........and want more all the time. You have Genmabic i think my doctor called it!:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind